Taken together, these data suggest that the inhibition of C3aR should be tested as a new immunotherapeutic approach for NK cell–based immunotherapy against pancreatic cancer, but for optimal results, a combination with radiotherapy is needed. This evidence concerns the gene C3AR1 and familial pancreatic carcinoma.